PANORAMA™ PRENATAL SCREENING TEST
Panorama is a non-invasive prenatal test (NIPT) that analyses fetal–placental cell-free DNA (cfDNA) isolated from maternal blood plasma and screens for various fetal chromosomal abnormalities. These include trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), monosomy X (Turner syndrome), sex-chromosome trisomies (XXX, XXY, XYY), triploidy and five microdeletion syndromes, including 22q11.2 deletion (DiGeorge syndrome), cri-du-chat syndrome, Prader–Willi syndrome, Angelman syndrome and 1p36 deletion syndrome. Fetal sex can also be reported on request. Panorama can be performed with high accuracy from nine weeks of pregnancy.
FREQUENCY OF CHROMOSOMAL ABNORMALITIES
Trisomy 21, trisomy 18 and trisomy 13 are the three most common aneuploidies. Together, they occur in approximately 1 in 450 live births. Trisomy 21, or Down syndrome, is the most common of the three. Microdeletions, microscopic losses of segments of chromosomal material, occur in newborns much more frequently than previously thought. The combined prevalence at birth of the five microdeletion syndromes covered by the Panorama test is approximately 1 in 1,000. The most common clinically significant microdeletion, 22q11.2 deletion syndrome (DiGeorge syndrome), occurs more frequently than cystic fibrosis (Figure 1).
TRADITIONAL SCREENING METHODS
Until recently, the principal approach to prenatal genetic screening for fetal chromosomal abnormalities included measuring biochemical markers in maternal serum in the first and/or second trimester, combined with first-trimester ultrasonography to measure sonographic markers of chromosomal abnormalities — nuchal translucency (NT) and/or nasal bone length. Although this combined screening test was designed to detect fetal trisomy 21, it can also detect trisomy 18 and trisomy 13. Increased NT (as well as cystic hygroma and other ultrasound markers) may indirectly indicate a fetal chromosomal abnormality; such signs can sometimes occur with a 22q11.2 microdeletion. According to the cited multicentre studies, traditional screening tests detect only 79–90% of Down syndrome cases prenatally, with a false-positive rate of 4–5%. The positive predictive value (PPV) — the probability that a high-risk result is a true positive — for trisomy 21 with traditional screening is less than 5%. Thus, of every 20 women receiving a positive or 'high genetic risk' screening result, at least 19 have a false-positive result. Traditional screening methods are not designed to detect microdeletions. Unlike aneuploidies, microdeletion syndromes have no reliably established markers detectable by maternal serum biochemical screening. Many of these syndromes also lack major structural malformations that could be found by ultrasound. Prenatal diagnosis of microdeletion syndromes requires an invasive procedure, namely amniocentesis or chorionic villus sampling (CVS), to obtain cells for subsequent analysis by fluorescence in situ hybridization (FISH) using DNA probes targeting the relevant chromosomal regions, or by genome-wide chromosomal microarray analysis. CVS and amniocentesis with standard karyotyping alone (without FISH or microarray) do not detect these microdeletions. Guidance from the UK's Fetal Medicine Foundation (FMF) states that chromosomal microarray is a first-line test for pregnant patients undergoing invasive testing, regardless of maternal age or the indication for the invasive procedure. However, every invasive procedure entails some risk of pregnancy loss, quoted in the source as between 1 in 450 and 1 in 900; therefore, undertaking such procedures requires a strong reason to suspect a fetal genetic abnormality. Because effective non-invasive prenatal screening methods had previously been unavailable, some women gave birth to children with chromosomal abnormalities despite normal genetic screening results. Such limitations occur with any screening test: for example, combined screening misses one in ten fetuses with Down syndrome, while the Delfia Express test misses one in twenty. Consequently, there is an obvious need for a prenatal screening method that is accurate, safe and non-invasive for all pregnant women regardless of age or additional risk factors.
NON-INVASIVE DETECTION OF FETAL CHROMOSOMAL ABNORMALITIES USING CELL-FREE DNA
Non-invasive prenatal tests analysing cell-free DNA (cfDNA) in maternal plasma revolutionized screening for FETAL chromosomal abnormalities. Because fetal cfDNA crosses the placental barrier and enters the mother's bloodstream, a simple maternal blood draw makes it possible to detect fetal chromosome copies without exposing the fetus to risks associated with invasive procedures. The cfDNA analysed is a mixture of maternal and fetal DNA; the percentage of fetal DNA is called the 'fetal fraction'. It has been shown that the fetal fraction correlates positively with gestational age and negatively with maternal weight.
Accurate assessment of fetal chromosome copy number from cell-free DNA isolated from maternal plasma requires amplification followed by bioinformatic analysis. There are two main approaches. The first is the quantitative, chromosome-counting methodology used in many first-generation cfDNA tests. The second, used by Natera, is a genotyping approach based on single-nucleotide polymorphisms (SNPs). Instead of relying solely on the relative counts of chromosome fragments, the SNP-based method also evaluates genetic variation to distinguish maternal and placental contributions.
FIRST GENERATION: COUNTING METHODOLOGY
Quantitative counting methods compare the relative number of sequence reads from a chromosome of interest, for example chromosome 21 (whose trisomy causes Down syndrome), against a reference chromosome or set of chromosomes assumed to be euploid (to have the normal chromosome number). Although effective for detecting trisomy 21 and trisomy 18, this approach is less successful with trisomy 13 or sex-chromosome aneuploidies. Counting cannot detect triploidy (three complete chromosome sets), estimated at approximately one in 2,000 pregnancies before 12 weeks, which can cause severe placental and fetal abnormalities and is associated with increased risks of spontaneous miscarriage, pre-eclampsia and gestational trophoblastic neoplasia. Counting also cannot distinguish maternal from fetal genotypes, potentially causing problems when the mother has duplications or other chromosomal abnormalities, including false-positive fetal results. The method cannot identify a vanishing twin. Because fetal cfDNA actually originates from the placenta, fetal and placental DNA may differ genetically because of confined placental mosaicism. This type of mosaicism occurs in 1–2% of pregnancies and can produce false-negative or false-positive results with both counting and SNP-based methods.
SECOND GENERATION: SNP-BASED METHODOLOGY
Panorama is described as the only available SNP-based non-invasive prenatal screening (NIPT) approach for determining ploidy (the number of chromosome sets). This approach distinguishes maternal from fetal DNA in plasma, sequences the DNA and analyses the fetal component, providing more reliable fetal-genotype information and greater accuracy at fetal fractions of 2.8% and above. Panorama genotypes 13,392 SNPs across chromosomes 21, 18, 13, X and Y; additional SNP panels target five microdeletions. After genotyping, a proprietary algorithm screens for fetal chromosomal abnormalities and fetal sex. The ability to distinguish maternal and fetal cfDNA also enables Panorama to identify vanishing-twin syndrome and maternal chromosomal duplications, potentially revealing a previously undetected microdeletion in the mother herself, such as 22q11.2 deletion syndrome. Because Panorama does not require a reference chromosome, the test can uniquely detect triploidy and a completely normal pregnancy.
The validation study for chromosomes 13, 18, 21, X and Y reported sensitivity of 100% for trisomy 21, 96% for trisomy 13 and 90% for trisomy 18 and monosomy X; the specificity for each indication was at least 99.9%.
A validation study of prenatal microdeletion detection reported sensitivity above 97% and specificity above 99% for each of the five microdeletion types. Clinical validation of microdeletion detection is ongoing.
CLINICAL APPLICATION
Panorama testing can be carried out from nine weeks of pregnancy and requires only a maternal blood sample. Special blood collection tubes that preserve cfDNA are used. Samples are shipped at room temperature to Natera's CLIA- and CAP-certified laboratory in San Carlos, California, USA. Following analysis, a report lists the individual's genetic risk for each chromosome assessed. Fetal sex is reported if requested; when ordered, individual risk levels for microdeletion syndromes are also provided. If Panorama indicates high risk, subsequent genetic counselling and confirmation of the fetal diagnosis through an invasive diagnostic procedure are recommended.
Both the validation study and the clinical validation study for Panorama included large samples of women from the general pregnant population. These studies showed that the positive predictive value (PPV) of Panorama was the same in pregnancies with high and low prior genetic risk of fetal chromosomal abnormalities. Because microdeletions arise independently of maternal age and other traditional risk factors, Panorama may serve as a useful screening tool for pregnant women generally.
CONCLUSIONS
Panorama has high sensitivity and specificity for detecting trisomy 21, trisomy 18, trisomy 13, monosomy X and triploidy, as well as for determining fetal sex, and offers early assessment. The screening test can also detect sex-chromosome trisomies. Compared with traditional screening, Panorama's low false-positive rate may reduce the number of invasive diagnostic procedures undertaken. Panorama has also been validated as a screening tool for common microdeletions, including 22q11.2 deletion (DiGeorge syndrome), 1p36 deletion, cri-du-chat syndrome, Prader–Willi syndrome and Angelman syndrome. For expectant parents wishing to learn more about their baby's health, the source presents Panorama as an accurate non-invasive way to screen for common chromosomal abnormalities early in pregnancy.
Benefits of Panorama NIPT
Screening from early pregnancy
From 9 weeks of pregnancy
Non-invasive for mother and fetus
- Routine venous blood draw
- A trained healthcare professional collects the sample
Convenient access from different cities
Ask our consultant about collection kits
Fast
10–14 working days
High screening accuracy
- Low false-positive rate
- SNP-based method distinguishes maternal and placental DNA
Fetal fraction (placental DNA proportion)
- Analysis considers maternal and placental DNA
- A sufficient fetal fraction is required for a result
Have a question?
Let us discuss it. Complete the form and our specialist will answer your questions.
We serve patients across Georgia!